X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (85) 85
hematology (73) 73
female (72) 72
middle aged (70) 70
male (65) 65
adult (62) 62
index medicus (57) 57
transplantation (57) 57
aged (51) 51
oncology (41) 41
immunology (37) 37
treatment outcome (34) 34
chemotherapy (31) 31
cancer (29) 29
multiple myeloma (26) 26
antineoplastic combined chemotherapy protocols - therapeutic use (25) 25
stem cells (24) 24
hematopoietic stem cells (23) 23
therapy (23) 23
disease-free survival (22) 22
hematopoietic stem cell transplantation (22) 22
adolescent (20) 20
care and treatment (20) 20
article (19) 19
multiple myeloma - therapy (19) 19
transplantation, autologous (19) 19
stem-cell transplantation (18) 18
survival analysis (18) 18
analysis (17) 17
antineoplastic combined chemotherapy protocols - administration & dosage (17) 17
retrospective studies (17) 17
combined modality therapy (16) 16
cyclophosphamide (16) 16
hematology, oncology and palliative medicine (16) 16
survival rate (16) 16
bone marrow (15) 15
bortezomib (15) 15
bone-marrow transplantation (14) 14
bone-marrow-transplantation (14) 14
hematopoietic stem cell transplantation - methods (14) 14
research (14) 14
aged, 80 and over (13) 13
carmustine - administration & dosage (13) 13
high-dose chemotherapy (13) 13
leukemia, myeloid, acute - drug therapy (13) 13
remission induction (13) 13
young adult (13) 13
aml (12) 12
follow-up studies (12) 12
stem cell transplantation (12) 12
hematopoietic stem cell transplantation - adverse effects (11) 11
recurrence (11) 11
survival (11) 11
transplantation, homologous (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
cyclophosphamide - administration & dosage (10) 10
dose-response relationship, drug (10) 10
prospective studies (10) 10
acute myeloid-leukemia (9) 9
colony-stimulating factor (9) 9
etoposide (9) 9
etoposide - administration & dosage (9) 9
melphalan - administration & dosage (9) 9
risk factors (9) 9
transplantation conditioning - methods (9) 9
versus-host-disease (9) 9
abridged index medicus (8) 8
antimitotic agents (8) 8
antineoplastic agents (8) 8
dexamethasone (8) 8
health aspects (8) 8
leukemia (8) 8
lymphoma, non-hodgkin - therapy (8) 8
mortality (8) 8
patient outcomes (8) 8
trial (8) 8
autografts (7) 7
breast neoplasms - therapy (7) 7
cohort studies (7) 7
drug administration schedule (7) 7
graft vs host disease - prevention & control (7) 7
hematopoietic stem cell mobilization - methods (7) 7
high-dose therapy (7) 7
leukemia, myeloid, acute - therapy (7) 7
multiple myeloma - mortality (7) 7
multiple-myeloma (7) 7
prognosis (7) 7
relapse (7) 7
thalidomide - analogs & derivatives (7) 7
transplantation, homologous - methods (7) 7
amd3100 (6) 6
antineoplastic agents - therapeutic use (6) 6
azacitidine - administration & dosage (6) 6
blood progenitor cells (6) 6
bone marrow transplantation (6) 6
combination (6) 6
cytarabine - administration & dosage (6) 6
dosage and administration (6) 6
g-csf (6) 6
granulocyte colony-stimulating factor - administration & dosage (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 21, pp. 2023 - 2036
Journal Article
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 9, pp. 1801 - 1809
Journal Article
Journal Article
Clinical Chemistry, ISSN 0009-9147, 04/2012, Volume 58, Issue 4, pp. 675 - 675
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 02/2017, Volume 15, Issue 2, pp. 230 - 230
Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal... 
SINGLE-AGENT CARFILZOMIB | INTERGROUPE FRANCOPHONE | DONOR LYMPHOCYTE INFUSIONS | INDUCTION THERAPY | ONCOLOGY | BORTEZOMIB PLUS DEXAMETHASONE | HIGH-DOSE THERAPY | INTERNATIONAL STAGING SYSTEM | TERM-FOLLOW-UP | STEM-CELL TRANSPLANTATION | LENALIDOMIDE MAINTENANCE
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 04/2018, Volume 24, Issue 4, pp. 687 - 693
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 04/2016, Volume 14, Issue 4, pp. 389 - 400
These NCCN Guidelines Insights highlight the important updates/changes specific to the 2016 version of the NCCN Clinical Practice Guidelines in Oncology for... 
CARFILZOMIB | INDUCTION THERAPY | ONCOLOGY | CYCLOPHOSPHAMIDE | INTERNATIONAL STAGING SYSTEM | LENALIDOMIDE | PHASE-II | COMBINATION | ORAL PROTEASOME INHIBITOR | PANOBINOSTAT PLUS BORTEZOMIB | LOW-DOSE DEXAMETHASONE
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 01/2018, Volume 16, Issue 1, pp. 11 - 20
The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, evaluation, treatment, including supportive-care, and follow-up for patients... 
ONCOLOGY | CYCLOPHOSPHAMIDE | RANDOMIZED PHASE-III | SURVIVAL ANALYSIS | NEWLY-DIAGNOSED MYELOMA | OPEN-LABEL | BORTEZOMIB | INDUCTION | STEM-CELL TRANSPLANTATION | LENALIDOMIDE MAINTENANCE | DEXAMETHASONE COMBINATION
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 11/2015, Volume 13, Issue 11, pp. 1398 - 1435
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. Recent statistics... 
SINGLE-AGENT CARFILZOMIB | DONOR LYMPHOCYTE INFUSIONS | THALIDOMIDE PLUS DEXAMETHASONE | INDUCTION THERAPY | ONCOLOGY | HIGH-DOSE THERAPY | LONG-TERM SURVIVAL | NEWLY-DIAGNOSED MYELOMA | PHASE-III | NATIONAL-CANCER-INSTITUTE | STEM-CELL TRANSPLANTATION
Journal Article
Cancer, ISSN 0008-543X, 02/2018, Volume 124, Issue 4, pp. 816 - 825
Journal Article
Blood, ISSN 0006-4971, 05/2017, Volume 129, Issue 19, pp. 2680 - 2692
Journal Article
Cancer, ISSN 0008-543X, 11/2018, Volume 124, Issue 22, pp. 4342 - 4349
Journal Article